Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Liver resection Clear all

Conditions: Adult Hepatocellular Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions: Computed Tomography, 18F-fluoromethylcholine, Positron Emission Tomography; Diagnostic Test · Drug
Lead sponsor: Queen's Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Colorectal Neoplasms, Neoplasm Metastasis, Hepatic Neoplasms
Interventions: Microwave ablation, Hepatic resection; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Recurrent Colorectal Carcinoma, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy, Quality-of-Life Assessment, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Cancer
Interventions: Perihepatic Phlebotomy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 184
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Postoperative chemotherapy, Perioperative chemotherapy; Procedure
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 283
States / cities: Antioch, California • Duarte, California • Fremont, California + 210 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Testing of hepatic AAV Vector integration; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 15
States / cities: Rancho Cordova, California • Sacramento, California • San Francisco, California + 6 more

Conditions: Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Cisplatin, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more

Conditions: Liver Transplantation, HCC, Oncological Outcomes
Interventions: Hypothermic oxygenated perfusion, Conventional cold storage; Procedure
Lead sponsor: Philipp Dutkowski; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Floxuridine, Intrahepatic Infusion Procedure, Leronlimab, Magnetic Resonance Imaging, Surgical Procedure, Systemic Therapy; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California

Conditions: Liver Cancer
Interventions: CO Testing Pre/Post Hepatic Resection, ABG Testing Pre/Post Hepatic Resection, CT Evaluations; Procedure · Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Glen Burnie, Maryland

Conditions: Liver Cancer
Interventions: nomogram-based selection for acute normovolemic hemodilution, standard selection for ANH based on a planned resection of 3 or more segments; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Hepatocellular Carcinoma
Interventions: Cabozantinib, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Cancer, Liver Metastases
Interventions: Not listed
Lead sponsor: Maastricht University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • Cleveland, Ohio

Conditions: Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: oxaliplatin, leucovorin calcium, fluorouracil, bevacizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, irinotecan hydrochloride; Drug · Biological · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Liver Resection, Colorectal Carcinoma Liver Metastases
Interventions: HRX215 capsules, Placebo capsules; Drug
Lead sponsor: HepaRegeniX GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Liver Transplantation
Interventions: Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
Interventions: Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery; Radiation · Dietary Supplement · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Neoplastic Disease, Solid Tumor
Interventions: Indocyanine Green; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Liver
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

HOPE Against Cancer Recurrence in HCC

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Safety of HRX215 in Patients After Minor and Major Liver Resection

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Indocyanine Green (ICG) Guided Tumor Resection

Trial Comparing PLA to HIGRT (PROVE-HCC)

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT